JPRN-UMIN000051448招募中Unknown
Oral semaglutide vs DPP-4i on body weight in Japanese people with type 2 diabetes - OSCAR-DWD study
Dokkyo Medical University Department of Endocrinology and Metabolism0 个研究点目标入组 70 人开始时间: 2023年6月26日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)No treatment with other GLP-1R analogue 8)Patient with intolerance of medical reasons by doctor.
研究者
相似试验
已完成
不适用
Effects of Dapagliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus. SUMS-ADDIT-2Type 2 diabetesJPRN-UMIN000020239Shiga University of Medical Science52
尚未招募
3 期
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®ObesityNCT06633783Hangzhou Jiuyuan Gene Engineering Co. Ltd.,370
已完成
4 期
SUMS-ADDIT-2Type 2 Diabetes MellitusJPRN-jRCTs051180018Morino Katsutaro52
已完成
不适用
Effects of Ipragliflozin on Body Weight in Japanese Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Insulin TherapyType 2 diabetesJPRN-UMIN000018839Shiga University of Medical Science50
已完成
3 期
Effect and safety of NN9535 in weight management (NN9536-4382)JPRN-jRCT2080224531ovo Nordisk Pharma Ltd.401